Last October, a 42-year-old strength coach named Derek in Austin told me he'd been running solo ipamorelin at 300 mcg nightly for six weeks. Sleep was better, recovery was "maybe 15% improved," but he felt like he'd hit a ceiling. His prescribing clinician added CJC-1295 no-DAC at 100 mcg to the same syringe. "By week three on the combo, I was sleeping like I did at 25 and my body comp started shifting in a way it hadn't from ipamorelin alone," he said. "It wasn't dramatic. It was just... real."
That experience tracks with what the pharmacology predicts. The ipamorelin and CJC-1295 stack has become the default starting combination in compounded peptide protocols for a reason: the two peptides work on different receptors, and together they produce a bigger, longer growth hormone (GH) pulse than either one manages solo. It's not magic. It's receptor math. Both are non-FDA-approved and dispensed by licensed compounding pharmacies for individual patients under prescription. Individual results vary.
How the Two Peptides Actually Work Together
The mechanism is straightforward once you stop overcomplicating it.
Ipamorelin is a GHSR-1a agonist, meaning it mimics ghrelin at the growth hormone secretagogue receptor. CJC-1295 is a GHRH analog, meaning it acts at the growth hormone releasing hormone receptor. Different locks, different keys. When both pathways fire at the same time, the pituitary gets a louder, clearer signal to release GH than it does from either peptide alone.
Teichman SL et al. (2006) originally characterized CJC-1295 and documented its capacity to sustain elevated GH and IGF-1 levels. Raun K et al. (1998) established ipamorelin's selectivity profile, showing it nudges GH release without dragging cortisol or prolactin along for the ride. Put them together and you get amplified GH output with a clean side-effect profile. That's the whole pitch, and it holds up.
Why This Pairing and Not Some Other Combo
Three things make the stack work where other combinations create problems:
No receptor competition. Because ipamorelin hits GHSR-1a and CJC-1295 hits GHRH-R, they don't elbow each other out. Two distinct upstream signals converging on the same downstream outcome.
Amplification, not just addition. Published research shows ghrelin-receptor activation potentiates GHRH-driven release. The combined pulse is more than the sum of its parts.
Tolerability. This is the part people underestimate. Ipamorelin is the cleanest GHSR-1a agonist in comparison data (no meaningful cortisol or prolactin bump). CJC-1295 provides sustained GHRH signaling without the chronic-elevation risks of exogenous GH. The stack inherits both peptides' favorable safety characteristics.
The DAC Question (This Is the Most Practical Decision You'll Make)
There are two versions of CJC-1295, and picking the wrong one for your goals is the single most common mistake I see.
Get provider-reviewed GLP-1 therapy
Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.
Start Free Assessment →CJC-1295 no-DAC (Modified GRF 1-29) has a half-life of roughly 30 minutes. You dose it at 100 to 300 mcg per injection, paired with each ipamorelin shot. It creates a sharp, pulsatile GH release that mimics what your pituitary does naturally in deep sleep. Think of it like tapping the gas pedal: quick bursts, closer to physiological rhythm.
CJC-1295 with DAC has a half-life of 6 to 8 days. You dose it at 1 to 2 mg per week, usually split across two injections. It elevates GH baseline continuously, with ipamorelin layered on top daily to provide pulse peaks above that raised floor. More like setting cruise control and then occasionally flooring it.
Most clinicians steer new patients toward no-DAC. It's more conservative, preserves natural pulsatility, and gives a cleaner picture of how the patient responds. DAC is convenient (fewer injections of that component) but produces a less physiological signaling pattern. The prescribing clinician decides, but if nobody's given you a strong reason for DAC, no-DAC is the boring, correct starting point.
Dosing Protocols: What a Typical Cycle Actually Looks Like
No-DAC stack (the most common starting protocol):
- CJC-1295 no-DAC: 100 to 200 mcg per injection
- Ipamorelin: 200 to 300 mcg per injection
- Both drawn into the same insulin syringe, injected subcutaneously
- Timing: pre-bed every night (non-negotiable), with an optional second dose post-workout or fasted morning
- Frequency: once or twice daily, 5 to 7 days per week
- Cycle length: 8 to 12 weeks on, 4 weeks off
DAC stack:
- CJC-1295 with DAC: 1 to 2 mg total per week, split into two injections (e.g., Monday and Thursday)
- Ipamorelin: 200 to 300 mcg daily, independent of DAC schedule
- Timing: ipamorelin pre-bed daily; DAC on its own fixed schedule
- Cycle length: 8 to 12 weeks on, 4 weeks off
- The two peptides are usually injected separately here because the schedules don't align
For no-DAC protocols, drawing both peptides into the same syringe is standard practice. Reconstitute each vial with bacteriostatic water (typical concentration: 5 mg lyophilized peptide plus 2 mL bac water, yielding 2.5 mg/mL). Draw ipamorelin first, then CJC-1295 into the same syringe, inject subcutaneously into a rotated site. One stick instead of two. That matters when you're doing this every night.
What to Expect, and When
Here's the thing about peptide timelines: people either expect miracles by day three or write the stack off because they didn't wake up looking like a superhero. The realistic arc looks more like this:
Weeks 1 to 2: Sleep changes are usually the first thing people notice. Falling asleep faster, sleeping deeper, waking up feeling more rested. Some mild headache as the body adjusts, especially in the first few days. This is normal and usually self-limiting.
Weeks 2 to 4: Recovery between training sessions improves. Energy levels trend upward. Nothing you'd call dramatic, more like the removal of friction.
Weeks 4 to 8: Body composition shifts start showing up for many people. Less abdominal softness, slightly better muscle definition on the same training program. The changes are gradual enough that progress photos help more than the mirror.
Weeks 8 to 12: Benefits plateau or stabilize. This is where the cycle ends.
Post-cycle: 4-week off period. Some people report a mild dip in sleep quality during the first week off, then normalization.
Skin and connective tissue improvements come slower, often requiring multiple cycles to become noticeable. If you're chasing skin benefits specifically, set expectations over a 6-month horizon, not a 12-week one.
Side Effects: What Actually Gets Reported
The stack shares ipamorelin's tolerability profile, which is its strongest selling point versus other secretagogue combinations. The most commonly reported side effects:
- Mild headache during the first one to two weeks (the single most common complaint)
- Slight water retention, more pronounced with DAC than no-DAC
- Injection-site irritation (rare with proper technique and site rotation)
- Mild nausea at higher doses
- Vivid dreams (most people actually like this one)
Cortisol and prolactin remain unaffected in published data, which is why ipamorelin gets chosen over hexarelin or GHRP-6 for this stack. The selectivity matters.
Who This Stack Fits (and Who It Doesn't)
Good candidates tend to be adults 35 and older with declining natural GH output, consistent training habits, adequate protein intake, and stable metabolic markers (insulin, thyroid). The stack rewards consistency; it's a tool for people already doing the work.
Poor candidates: anyone with active or recent malignancy (any GH-axis intervention is generally contraindicated), poorly controlled diabetes, or an expectation that peptides will substitute for training and nutrition. Also a poor fit for anyone who can't commit to daily injections across 8 to 12 weeks. Inconsistent dosing defeats the purpose. Think of it like antibiotics: skipping days doesn't give you a partial benefit, it gives you a compromised result.
Layering With Other Peptides
The ipamorelin plus CJC-1295 stack is sometimes combined with non-GH peptides for specific goals:
- BPC-157 for joint and tissue support
- TB-500 for recovery support
- GHK-Cu for skin and connective tissue
- Tesamorelin is an alternative GHRH analog but is generally not combined with CJC-1295 (overlapping mechanism)
Layered protocols need direct clinical oversight. Stacking three or four peptides based on forum advice is how people end up confused about what's doing what and unable to troubleshoot when something doesn't work.
Mistakes That Waste Your Money
A short list of errors that come up repeatedly:
- Using the DAC version on a no-DAC schedule (completely wrong half-life model)
- Running the stack continuously past 12 weeks without cycling off
- Skipping days regularly ("I only missed a few" still blunts the cumulative signal)
- Dosing right after a fatty meal (blunts the GH pulse significantly)
- Reconstituting with sterile water instead of bacteriostatic water (shorter shelf life, higher contamination risk)
- Restarting after a long break at full dose instead of re-titrating upward
FAQ
Should I use DAC or no-DAC?
For most patients starting the stack, no-DAC is the safer and more physiological choice. It preserves natural pulsatile GH release patterns. DAC is more convenient (fewer total injections of that peptide) but creates a less natural signaling profile. Your prescribing clinician will make the final call based on your labs and goals.
How long does the stack take to show effects?
Sleep and recovery improvements: 1 to 4 weeks. Body composition changes: 4 to 12 weeks. Skin and connective tissue: often multiple cycles, so 4 to 6 months or longer.
Can I take the stack every day indefinitely?
No. Most clinicians cycle 8 to 12 weeks on, 4 weeks off. Continuous year-round dosing lacks human safety data, and receptor desensitization becomes a concern. The off-period is part of the protocol, not optional.
Do I need bloodwork during the stack?
Baseline labs should include IGF-1, fasting glucose, HbA1c, TSH, and a lipid panel. A mid-cycle IGF-1 recheck is the most useful response marker. It tells you and your clinician whether the stack is actually moving the needle.
What if I don't respond well?
Document specifics (sleep quality, energy, training performance, any side effects), complete the planned cycle, and review with your prescribing clinician. Adjusting timing, frequency, or stack composition resolves most underresponse issues before a peptide swap becomes necessary.
Can both peptides go in the same syringe?
For no-DAC protocols, yes. Draw ipamorelin first, then CJC-1295 no-DAC into the same insulin syringe. For DAC protocols, the injections are usually separate because the dosing schedules don't overlap.
Is there a best time of day to inject?
Pre-bed is the universal recommendation. GH release is naturally highest during deep sleep, and timing the injection to coincide with that window amplifies the effect. A second optional dose can be added fasted in the morning or post-workout.
Related Reading
---
Disclaimer: Ipamorelin and CJC-1295 are not FDA-approved. They are compounded research peptides dispensed by licensed pharmacies for individual patients under a valid prescription. This article is for educational purposes and does not constitute medical advice. Individual results vary. Always consult a licensed prescribing clinician before starting any compounded peptide protocol.
Citations: Raun K et al. 1998 (ipamorelin); Teichman SL et al. 2006 (CJC-1295).